Even among cancers, pancreatic cancer is an especially sinister form of disease. The one-year survival rate is extremely low, and treatment progress has lagged behind that of many other malignancies.
A study published today in the journal Nature Medicine led by researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) describes a new therapeutic approach with potential for patients with pancreatic cancer. These researchers discovered a combination drug therapy that may effectively combat the disease. HCI researchers first observed anti-cancer impacts in a laboratory setting and, subsequently, in its first use in a human patient.
The study has already progressed to a clinical trial that is now open at HCI and will soon be open at other sites in the United States. Details about the clinical trial, called THREAD, are available under National Clinical Trial Number 03825289. The combination therapy uses two drugs already approved for use by the Food and Drug Administration for other diseases, including cancer. The new drug combination is administered through pills taken orally.
Pancreatic tumors are characterized by mutations in a gene called KRAS. When KRAS is mutated in this way, it sends constant signals that promote abnormal cell division and growth in cancer cells. As a result, tumors grow out of control. At the same time, like all cells, pancreatic cancer cells must recycle their components to provide building blocks for new growth in an essential cell function known as autophagy. Previous studies to combat pancreatic cancer that were focused either on the role of KRAS or on impacting autophagy were not effective.
The new HCI study, using an approach that simultaneously targets both abnormal KRAS signaling and the autophagy process, shows a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer. Conan Kinsey, MD, PhD, a physician-scientist at Huntsman Cancer Institute and the Department of Internal Medicine at the U of U and Martin McMahon, PhD, a cancer researcher at HCI and Professor of Dermatology at the U of U, led the study.
“We were able to observe that the combination of these two drugs – which, when used individually, don’t have much of an impact on the disease – appears to have a very potent impact on the growth of pancreatic cancer,” says McMahon. “We have observed this in the lab in petri dishes, then in mouse models, and now in a pancreatic cancer patient on a compassionate use basis. Indeed, we proceeded from a petri dish to a patient in less than two years – a timeline that is rarely seen in medical science.”
The HCI-led research is bolstered by a separate study published in the same issue of the journal. This study outlines complementary findings regarding the effects of autophagy in pancreatic cancer in the laboratory setting and was led by Channing Der, PhD, Sarah Graham Kenan, PhD, and Kirsten Bryant, PhD, at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. McMahon and Der learned about the parallel nature of their research programs at a scientific meeting one year ago. Given the critical need for advances in pancreatic cancer therapies and the promise of their collective findings, they worked together to push their studies forward on a companion basis.
“In our paper, we show the response of a pancreatic cancer patient who had received surgery and multiple lines of chemotherapy prior to this combination,” said Kinsey, who was also the patient’s physician. “This patient, who has since succumbed to the disease, nevertheless had a remarkable response to these drugs for several months. We need to carefully evaluate this new combination therapy in the context of clinical trials to better understand if good responses might be seen in multiple patients. We also need to identify the specific features of any patient who may benefit, before any recommendation can be made about use on a larger scale.”
These preliminary findings are being rigorously scrutinized in clinical trials to observe and understand whether the combination of these drugs is safe and effective for pancreatic cancer patients. The trial is underway at HCI and is underway or planned at the University of California, San Francisco, and Columbia University in New York.
“In publishing how this new approach of mixing two medicines typically associated with malaria and melanoma can treat pancreatic tumors with KRAS mutations, we are hoping the clinical trial supported by the Pancreatic Cancer Collective’s New Therapies Challenge Grant will help us learn how to best administer these medicines, so that we can maximize the benefit for as many patients as possible,” said David Tuveson, MD, PhD, Lustgarten’s Chief Scientist, Director of the Cancer Center at Cold Spring Harbor Laboratory, Co-Scientific Leader of the Collective.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Israeli researchers use novel methods to seek treatments for deadly pancreatic canceron January 12, 2021 at 8:41 am
In his wife’s memory, Kenneth Goodman established the Barbara S. Goodman Endowed Research Career Development Award for Pancreatic Cancer at the Israel Cancer Research Fund, which supports scientific ...
- Record Drop In Cancer Mortality Reported For Second Straight Yearon January 12, 2021 at 8:27 am
The drop is underpinned by significant progress in lung cancer treatment, although it still remains the #1 cause of death from cancer.
- Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposiumon January 12, 2021 at 1:47 am
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary data from the ongoing ...
- Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancerson January 12, 2021 at 1:44 am
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today ...
- Siegfried Fischbacher 'is terminally ill with pancreatic cancer' months after Roy died from COVID-19on January 11, 2021 at 12:24 pm
Siegfried was 'released from a clinic at his own request' and is being taken care of by 'two hospice workers' at home in Las Vegas just nine months after his partner, Roy, died from COVID-19.
- Vikings' Adam Thielen Donating Alex Trebek Cleats for Pancreatic Cancer Charityon January 8, 2021 at 6:11 pm
Minnesota Vikings wide receiver Adam Thielen is auctioning off a pair of custom-made cleats he wore in November to honor host ...
- Global Pancreatic Cancer Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.comon January 7, 2021 at 3:57 am
Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Pancreatic cancer is currently ...
- Opioid use may increase the risk of pancreatic canceron January 6, 2021 at 3:41 pm
Researchers at Rush University Medical Center have found that opioid use might increase a person's risk of developing pancreatic cancer.
- The link between opioid medication and pancreatic canceron January 6, 2021 at 1:59 pm
Using Center for Disease Control's national population health and cancer statistics datasets, Rush University Medical Center researchers determined that a state's opioid death rate significantly ...
- The Lustgarten Foundation and the AACR Honor Two American Icons Lost to Pancreatic Cancer with New Career Development Awards for Researcherson January 6, 2021 at 11:13 am
The Lustgarten Foundation and the American Association for Cancer Research (AACR) have established two new career development awards for ...
via Bing News